This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grey, A. Articles by Reid, I. R. Search for Related Content PubMed PubMed Citation Articles by Grey, A. Articles by Reid, I. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLECALCIFEROL PARATHYROID HORMONE Related Collections Calcium and Bone Metabolism

Vitamin D Repletion in Patients with Primary Hyperparathyroidism and Coexistent Vitamin D Insufficiency

Department of Medicine (A.G., J.L., A.H., G.G., I.R.R.), University of Auckland, 92019 Auckland, New Zealand; and Department of Chemical Pathology (J.S.D.), Labplus, Auckland City Hospital, Auckland, New Zealand

Address all correspondence and requests for reprints to: Associate Professor Andrew Grey, Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand. E-mail: a.grey{at}auckland.ac.nz; or James S. Davidson, Department of Chemical Pathology, Labplus, Auckland City Hospital, Private Bag 92-024, Auckland, New Zealand.

Vitamin D insufficiency is common in patients with primary hyperparathyroidism (PHPT) and may be associated with more severe and progressive disease. Uncertainty exists, however, as to whether repletion of vitamin D should be undertaken in patients with PHPT. Here we report the effects of vitamin D repletion on biochemical outcomes over 1 yr in a group of 21 patients with mild PHPT [serum calcium <12 mg/dl (3 mmol/liter)] and coexistent vitamin D insufficiency [serum 25 hydroxyvitamin D [25(OH)D] <20 µg/liter (50 nmol/liter)].

In response to vitamin D repletion to a serum 25(OH)D level greater than 20 µg/liter (50 nmol/liter), mean levels of serum calcium and phosphate did not change, and serum calcium did not exceed 12 mg/dl (3 mmol/liter) in any patient. Levels of intact PTH fell by 24% at 6 months (P < 0.01) and 26% at 12 months (P < 0.01). There was an inverse relationship between the change in serum 25(OH)D and that in intact PTH (r = –0.43, P = 0.056). At 12 months, total serum alkaline phosphatase was significantly lower, and urine N-telopeptides tended to be lower than baseline values (P = 0.02 and 0.13, respectively). In two patients, 24-h urinary calcium excretion rose to exceed 400 mg/d, but the group mean 24-h urinary calcium excretion did not change.

These preliminary data suggest that vitamin D repletion in patients with PHPT does not exacerbate hypercalcemia and may decrease levels of PTH and bone turnover. Some patients with PHPT may experience an increase in urinary calcium excretion after vitamin D repletion.

This article has been cited by other articles:

				F. Tassone, L. Gianotti, I. Emmolo, M. Ghio, and G. Borretta Glomerular Filtration Rate and Parathyroid Hormone Secretion in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4458 - 4461. [Abstract] [Full Text] [PDF]

				J R Tucci Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D Eur. J. Endocrinol., July 1, 2009; 161(1): 189 - 193. [Abstract] [Full Text] [PDF]

				R. Eastell, A. Arnold, M. L. Brandi, E. M. Brown, P. D'Amour, D. A. Hanley, D. S. Rao, M. R. Rubin, D. Goltzman, S. J. Silverberg, et al. Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 340 - 350. [Abstract] [Full Text] [PDF]

				P Iglesias and J J Diez Current treatments in the management of patients with primary hyperparathyroidism Postgrad. Med. J., January 1, 2009; 85(999): 15 - 23. [Abstract] [Full Text] [PDF]

				N. Farag, T. Delbanco, and G. J. Strewler Update: A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, November 5, 2008; 300(17): 2044 - 2045. [Full Text] [PDF]

				M. F. Holick Vitamin D Deficiency N. Engl. J. Med., July 19, 2007; 357(3): 266 - 281. [Full Text] [PDF]

				K. Zajickova, J. Vrbikova, L. Canaff, P. D. Pawelek, D. Goltzman, and G. N. Hendy Identification and Functional Characterization of a Novel Mutation in the Calcium-Sensing Receptor Gene in Familial Hypocalciuric Hypercalcemia: Modulation of Clinical Severity by Vitamin D Status J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2616 - 2623. [Abstract] [Full Text] [PDF]

				B Moosgaard, P Vestergaard, L Heickendorff, F Melsen, P Christiansen, and L Mosekilde Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur. J. Endocrinol., August 1, 2006; 155(2): 237 - 244. [Abstract] [Full Text] [PDF]

				R. Vieth Critique of the Considerations for Establishing the Tolerable Upper Intake Level for Vitamin D: Critical Need for Revision Upwards J. Nutr., April 1, 2006; 136(4): 1117 - 1122. [Abstract] [Full Text] [PDF]

				Y. Kinoshita, M. Taguchi, A. Takeshita, D. Miura, S. Tomikawa, and Y. Takeuchi 1,25-Dihydroxyvitamin D Suppresses Circulating Levels of Parathyroid Hormone in a Patient with Primary Hyperparathyroidism and Coexistent Sarcoidosis J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6727 - 6731. [Abstract] [Full Text] [PDF]